The Clear Path | Clinical Insights

Physician Narratives

Verheye Measures Whether Uncaging Compromises Deployment

By Rania Haddad— January 25, 2026

Feature image for article: Verheye Measures Whether Uncaging Compromises Deployment

Stefan Verheye measures robotic stent placement to fractions of millimeters. At ZNA Cardiovascular Center Middelheim, where he's evaluated coronary sinus reducers and bioresorbable magnesium scaffolds through over 170 peer-reviewed papers, his assessment framework stays consistent: deliverability matching operator expectations, conformability adapting to vessel anatomy without compromise, radial strength providing predictable scaffolding.

He designed the DynamX mechanistic study to answer what interventionalists needed to know first about a device engineered to unlock: whether they could trust the uncaging mechanism during deployment. His 50-patient Belgian-Italian study would measure if a cobalt-chromium stent incorporating adaptive remodeling could maintain conventional handling when operators needed predictable behavior most.

Physician Narratives

Verheye Measures Whether Uncaging Compromises Deployment

By Rania Haddad— January 25, 2026

Stefan Verheye measures robotic stent placement to fractions of millimeters. At ZNA Cardiovascular Center Middelheim, where he's evaluated coronary sinus reducers and bioresorbable magnesium scaffolds through over 170 peer-reviewed papers, his assessment framework stays consistent: deliverability matching operator expectations, conformability adapting to vessel anatomy without compromise, radial strength providing predictable scaffolding.

He designed the DynamX mechanistic study to answer what interventionalists needed to know first about a device engineered to unlock: whether they could trust the uncaging mechanism during deployment. His 50-patient Belgian-Italian study would measure if a cobalt-chromium stent incorporating adaptive remodeling could maintain conventional handling when operators needed predictable behavior most.

Physicians Championing Clinical Evidence

Manila Cardiologist Converts Skeptics With Three-Year Bioadaptor Data

Dr. Ramon Valdez walked into his Manila hospital's January 7th cardiology meeting carrying the three-year BIOADAPTOR-RCT results. The numbers were stark: 2.7% target lesion failure with DynamX versus 7.2% with standard drug-eluting stents.

His procurement director cut him off within minutes. "We already have three stent contracts."

Two senior partners piled on. Why justify premium pricing for 4.5% absolute risk reduction? Their patient population couldn't afford experimental technology.

Valdez pulled out the INFINITY-SWEDEHEART small vessel subset. Zero target lesion failures with DynamX. Zero. The room went quiet.

By Thursday, three colleagues had requested supervised cases. The department chair scheduled a February protocol review.

Physicians Championing Clinical Evidence

Manila Cardiologist Converts Skeptics With Three-Year Bioadaptor Data

Dr. Ramon Valdez walked into his Manila hospital's January 7th cardiology meeting carrying the three-year BIOADAPTOR-RCT results. The numbers were stark: 2.7% target lesion failure with DynamX versus 7.2% with standard drug-eluting stents.

His procurement director cut him off within minutes. "We already have three stent contracts."

Two senior partners piled on. Why justify premium pricing for 4.5% absolute risk reduction? Their patient population couldn't afford experimental technology.

Valdez pulled out the INFINITY-SWEDEHEART small vessel subset. Zero target lesion failures with DynamX. Zero. The room went quiet.

By Thursday, three colleagues had requested supervised cases. The department chair scheduled a February protocol review.

IN SUMMARY

Heated exchange:

Senior partner declared "patients won't pay premium for incremental benefit" during 45-minute debate, questioning whether cost-effectiveness justified disrupting established vendor relationships.

Evidence moment:

Valdez presented printed Lancet publication showing zero small vessel events, 0.5% cardiovascular death rate, plateauing event curves after six months versus 2-3% annual increase with conventional stents.

Institutional breakthrough:

Department chair agreed to March formulary committee presentation contingent on initial trial cases demonstrating handling advantages and patient acceptance of premium pricing.

Ripple effect:

Two referring cardiologists from affiliated community hospitals requested literature packets after treated patients mentioned superior small vessel outcomes during follow-up appointments.

Personal investment:

Valdez spent weekend creating comparison presentation, risking collegial relationships by challenging three existing vendor contracts and questioning adequacy of incumbent technology.

Cath Lab Insights: Procedural Advantages

When you're making the case for a new platform to your procurement committee, trial data matters. But so does the stuff you can't always capture in a protocol: how the device actually handles when you're working through tortuous anatomy, whether you can see what you need to see under fluoroscopy, if it behaves predictably in the cases that already make you nervous.

These are peer observations from the cath lab. Not marketing claims, just what interventional cardiologists are noticing about breakthrough coronary platforms in real-world use. The practical advantages that help you advocate for formulary inclusion when you're up against vendor incumbency and institutional purchasing agreements.

Cath Lab Insights: Procedural Advantages

When you're making the case for a new platform to your procurement committee, trial data matters. But so does the stuff you can't always capture in a protocol: how the device actually handles when you're working through tortuous anatomy, whether you can see what you need to see under fluoroscopy, if it behaves predictably in the cases that already make you nervous.

These are peer observations from the cath lab. Not marketing claims, just what interventional cardiologists are noticing about breakthrough coronary platforms in real-world use. The practical advantages that help you advocate for formulary inclusion when you're up against vendor incumbency and institutional purchasing agreements.

Tortuous Anatomy

Gets Where You Need It

Handles like the conventional platforms you're already using. I've pushed it through shepherd's crook RCAs and severely angulated LADs without the trackability issues you sometimes see with thicker-strut designs. The crossing profile matters when you're working through challenging anatomy—this doesn't fight you.

Acute Gain

Immediate Lumen Expansion Matches Metallic Platforms

You're not sacrificing anything on acute gain—1.61mm mean expansion with residual stenosis under 6%. That's comparable to what I see with contemporary metallic stents. The vessel gets the immediate scaffolding it needs, then the biology takes over later.

Fluoroscopic Visibility

Radiopaque Markers Do Their Job

Visibility under fluoro is adequate—the markers are clear enough for precise positioning even in heavily calcified segments. I haven't had issues with landing zone identification or post-deployment verification. It's not revolutionary, but it's not a limitation either.

Small Vessels

Zero TLF in Vessels ≤2.75mm

The INFINITY-SWEDEHEART data caught my attention: zero target lesion failure in small vessels at six months versus 1.8% with conventional DES. Small-vessel disease is where deliverability and vessel healing both matter—this platform seems to handle both challenges.

Vessel Motion

Natural Dynamics After Deployment

The vessel moves more naturally after uncaging—you can see it on follow-up imaging. Maintains radial strength when you need it, then allows physiologic motion as the polymer absorbs. That's the theoretical advantage, and it seems to translate into how vessels actually behave.

Complex Lesions

Real Experience in CTOs and Bifurcations

Thousands of cases now in complex anatomy—primary PCI, chronic total occlusions, bifurcations, calcified lesions. The thin struts and polymer coating handle like contemporary metallic platforms. Not claiming it's easier, just saying it's not harder in the cases that already challenge you.

Recent Evidence: Clinical Validation Studies

DynamX Bioadaptor Halves Late Failure Rates

INFINITY-SWEDEHEART trial shows DynamX Bioadaptor reduced target-lesion failure nearly 50% between six and 24 months versus conventional drug-eluting stents. Acute coronary syndrome patients saw particularly strong outcomes. The platform's polymer resorption allows vessels to regain natural motion during critical healing periods.

Why does this matter?

For procurement discussions: Dramatic late complication reduction during the vessel healing window when committees question long-term value propositions.

Who published this paper?

Clinical mechanism: Progressive vessel motion restoration as polymer degrades completely addresses permanently rigid metallic stent fundamental limitations.

Polymer-Free Stents Cut Five-Year MACE 22%

Network meta-analysis in JACC Advances demonstrates polymer-free titanium-nitride-oxide stents associated with 22% lower five-year major adverse cardiac event risk versus controls. Highest efficacy preventing stent thrombosis and myocardial infarction, the two most feared PCI complications physicians face.

Why does this matter?

Durability evidence: Five-year outcome data extends beyond typical one-year trial endpoints that dominate formulary discussions with procurement teams.

Who published this paper?

Clinical validation: Superior stent thrombosis and MI prevention confirms polymer-free platforms deliver meaningful innovation beyond marketing differentiation.

Drug-Eluting Balloons Match Stents for Restenosis

SELUTION4ISR randomized trial demonstrates sirolimus drug-eluting balloons non-inferior to standard care for in-stent restenosis: 15.2% versus 13.5% target lesion failure at 12 months. Avoids additional metallic layers in vessels that already failed once, preserving architecture for future interventions.

Why does this matter?

Leave-nothing-behind approach: Treats restenosis without adding metal layers, maintaining vessel integrity for potential subsequent interventions if needed.

Who published this paper?

Evidence strength: Companion SELUTION DeNovo trial in 3,000-plus patients demonstrates non-inferiority for de novo lesions, largest randomized balloon study.

Iron Bioresorbable Stents Match Metallic Performance

IRONMAN II multicenter randomized trial confirms sirolimus-eluting iron bioresorbable stents demonstrate angiographic and functional outcomes non-inferior to contemporary cobalt-chromium everolimus-eluting stents at two years. Study enrolled 518 patients across 36 centers, validating platform durability.

Why does this matter?

Platform evolution: Iron overcomes mechanical limitations and suboptimal clinical results that plagued first-generation polymer-based bioresorbable scaffolds completely.

Who published this paper?

Design advantage: Ultrathin 55-micrometer strut thickness approaches contemporary metallic profiles while maintaining theoretical advantages of complete bioresorption.

Recent Evidence: Clinical Validation Studies

DynamX Bioadaptor Halves Late Failure Rates

INFINITY-SWEDEHEART trial shows DynamX Bioadaptor reduced target-lesion failure nearly 50% between six and 24 months versus conventional drug-eluting stents. Acute coronary syndrome patients saw particularly strong outcomes. The platform's polymer resorption allows vessels to regain natural motion during critical healing periods.

Why does this matter?

For procurement discussions: Dramatic late complication reduction during the vessel healing window when committees question long-term value propositions.

Who published this paper?

Clinical mechanism: Progressive vessel motion restoration as polymer degrades completely addresses permanently rigid metallic stent fundamental limitations.

Recent Evidence: Clinical Validation Studies

Polymer-Free Stents Cut Five-Year MACE 22%

Network meta-analysis in JACC Advances demonstrates polymer-free titanium-nitride-oxide stents associated with 22% lower five-year major adverse cardiac event risk versus controls. Highest efficacy preventing stent thrombosis and myocardial infarction, the two most feared PCI complications physicians face.

Why does this matter?

Durability evidence: Five-year outcome data extends beyond typical one-year trial endpoints that dominate formulary discussions with procurement teams.

Who published this paper?

Clinical validation: Superior stent thrombosis and MI prevention confirms polymer-free platforms deliver meaningful innovation beyond marketing differentiation.

Recent Evidence: Clinical Validation Studies

Drug-Eluting Balloons Match Stents for Restenosis

SELUTION4ISR randomized trial demonstrates sirolimus drug-eluting balloons non-inferior to standard care for in-stent restenosis: 15.2% versus 13.5% target lesion failure at 12 months. Avoids additional metallic layers in vessels that already failed once, preserving architecture for future interventions.

Why does this matter?

Leave-nothing-behind approach: Treats restenosis without adding metal layers, maintaining vessel integrity for potential subsequent interventions if needed.

Who published this paper?

Evidence strength: Companion SELUTION DeNovo trial in 3,000-plus patients demonstrates non-inferiority for de novo lesions, largest randomized balloon study.

Recent Evidence: Clinical Validation Studies

Iron Bioresorbable Stents Match Metallic Performance

IRONMAN II multicenter randomized trial confirms sirolimus-eluting iron bioresorbable stents demonstrate angiographic and functional outcomes non-inferior to contemporary cobalt-chromium everolimus-eluting stents at two years. Study enrolled 518 patients across 36 centers, validating platform durability.

Why does this matter?

Platform evolution: Iron overcomes mechanical limitations and suboptimal clinical results that plagued first-generation polymer-based bioresorbable scaffolds completely.

Who published this paper?

Design advantage: Ultrathin 55-micrometer strut thickness approaches contemporary metallic profiles while maintaining theoretical advantages of complete bioresorption.

Navigating Hospital Formulary Inclusion Challenges

Contract Leverage When Your Hospital Favors Incumbent Vendors

Negotiation tactics and interoperability requirements that give physicians bargaining power against entrenched purchasing agreements favoring market leaders.

How Four Hospital Systems Actually Evaluate New Devices

Procurement committee interviews reveal the gap between stated evaluation criteria and real decision dynamics when clinical evidence confronts institutional inertia.

Decoding P&T Committees: Strategic Intelligence for Physician Advocates

Understanding Hospital Technology Assessment: The Evaluation Framework Explained

Structured Decision Analysis for Comparing Competing Device Platforms

Industry's Own Guide to Value-Based Procurement Decisions

Navigating Hospital Formulary Inclusion Challenges

Contract Leverage When Your Hospital Favors Incumbent VendorsNegotiation tactics and interoperability requirements that give physicians bargaining power against entrenched purchasing agreements favoring market leaders.

How Four Hospital Systems Actually Evaluate New DevicesProcurement committee interviews reveal the gap between stated evaluation criteria and real decision dynamics when clinical evidence confronts institutional inertia.

Quick links

Decoding P&T Committees: Strategic Intelligence for Physician Advocates

Understanding Hospital Technology Assessment: The Evaluation Framework Explained

Structured Decision Analysis for Comparing Competing Device Platforms

Industry's Own Guide to Value-Based Procurement Decisions